Menu

Developing Countries need support to Conduct Anonymous HIV Testing

Author: Public Library of Science
Published: 21 Jan 2009

Contents: Synopsis - Introduction - Main - Related Publications

Synopsis: Data collected from HIV surveillance are crucial to guide public health interventions planning and prevention efforts.

Introduction

Data collected from HIV surveillance are crucial to guide public health interventions, planning, and prevention efforts. But developing countries face several challenges to implementing surveillance programs says a team of researchers from the US and the Democratic Republic of Congo in this week's PLoS Medicine.

Main Content

Developing countries need support to ethically conduct unlinked anonymous HIV testing.

Data collected from HIV surveillance are crucial to guide public health interventions, planning, and prevention efforts. But developing countries face several challenges to implementing surveillance programs says a team of researchers from the US and the Democratic Republic of Congo in this week's PLoS Medicine.

One form of surveillance that can be particularly challenging to conduct, say Stuart Rennie (University of North Carolina at Chapel Hill, USA) and colleagues, is unlinked anonymous testing (UAT), which typically involves using blood that is discarded from specimens collected from patients for routine clinical purposes. UAT commonly does not involve obtaining consent from the person whose discarded blood is tested for HIV. The test is anonymized and unlinked from the person providing the sample and so the results cannot be reported back to patients.

The ethical justification for UAT, they say, includes the usefulness of the surveillance data together with the confidentiality protections afforded by anonymous, unlinked testing; the fact that the residual blood collected for other purposes would be discarded anyway and no one is harmed by its use; and the view that UAT takes place as part of a response to a public health emergency.

While the authors believe that UAT itself is "valuable and ethical," they argue that such surveillance "can be conducted in ethically questionable ways in certain circumstances." They give a series of examples from their own experience in the field, together with guidance on how to improve the conduct of UAT in such circumstances.

One example is that agencies conducting UAT in developing countries, they say, may sometimes collect residual blood from syphilis testing services that they temporarily set up to facilitate HIV surveillance. Such an approach is not in keeping with WHO/UNAIDS guidelines which state that UAT should only be conducted in settings where blood is regularly (not temporarily) collected for other purposes. "If syphilis testing is offered opportunistically to obtain blood for surveillance purposes," say Rennie and colleagues "then the primary purpose of the blood draw is not syphilis testing but surveillance, and consent should be obtained."

The authors outline three strategies to harmonize high quality HIV surveillance with international ethical standards. First, justifications for UAT should be reviewed in local contexts with local stakeholders. "The justifications," they say, "should be directly addressed in surveillance protocols, discussed with local ethics review boards, and communicated in community awareness meetings." Second, one ethical concern surrounding UAT namely that those whose blood tests positive for HIV do not know their HIV status could be addressed by providing confidential voluntary testing in close conjunction with UAT activities. Third, gaining local approval for HIV surveillance activities is important, but insufficient "beyond approval," they say "lies the fundamental ethical requirement to strengthen in-country capacity in epidemiological surveillance, ethics, and health care systems."

Reference

Rennie S, Turner AN, Mupenda B, Behets F (2009) Conducting unlinked anonymous HIV surveillance in developing countries: Ethical, epidemiological and public health concerns. PLoS Med 6(1): e1000004.

HIV Disparities for Those with Disabilities

Peer-reviewed study reveals HIV testing and treatment disparities among people with intellectual disabilities and Black patients with developmental disabilities. Published: 15 Feb 2024.

How Large HIV Protein Functions to Form Infectious Virus

Understanding how HIV replicates within cells is vital for developing new therapies that could help nearly 40 million people living with HIV globally. Published: 6 Jul 2022.

Paris Declaration to End AIDS Epidemic

On World AIDS Day 2014, mayors from around the world came together in Paris, France, to sign declaration to end AIDS epidemic in their cities. Published: 1 Dec 2014.

PRO 140 Monoclonal Antibody Drug for HIV Patients

PRO 140 may prove to be a potential new therapy for HIV patients who need to cycle off conventional treatment regimens. Published: 29 Oct 2014.

Cryptococcosis: Causes, Symptoms, Treatment

Cryptococcosis is an infection caused by inhaling the fungus Cryptococcus Neoformans and most often affects people with AIDS. Published: 9 May 2013.

Edurant FDA Approved HIV Treatment

The U.S. Food and Drug Administration has approved Edurant (rilpivirine) in combination with other anti-retroviral drugs for the treatment of HIV-1 infection in adults who have never taken HIV therapy. Published: 20 May 2011.

View the Full List of Related Publications

What People Are Saying

Start, or join, thought-provoking conversations with other Disabled World readers on this topic.

Share and Comment

Permalink:

<a href="https://www.disabled-world.com/health/aids/hiv-testing.php">Developing Countries need support to Conduct Anonymous HIV Testing</a>: Data collected from HIV surveillance are crucial to guide public health interventions planning and prevention efforts.

While we strive to provide accurate, up-to-date information, our content is for general informational purposes only. Please consult qualified professionals for advice specific to your situation.